Medicago has reported positive interim results from a Phase I human clinical trial of its H5N1 avian influenza vaccine candidate.

The vaccine was found to be safe, well tolerated and also induced a solid immune response, Medicago said.

A total of 48 healthy volunteers between the ages of 18 and 60 received two doses of either Medicago’s vaccine at doses of 5, 10 or 20 micrograms or a placebo.

No serious adverse effects were reported during the trial.